Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

Semaglutide Treats Liver Disease in Two Thirds of Patients Apr. 30, 2025 — Semaglutide effectively treats liver disease in two thirds of patients, new research has ... Apr. 15, 2025 ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

SAN FRANCISCO and SUZHOU, China, May 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...